Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® ...Middle East

STOCKHOLM, March 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug exclusivity period of seven years for TARPEYO®, expiring in December 2030 based on when the company obtained...

Hence then, the article about calliditas announces an additional seven year orphan drug exclusivity period for tarpeyo was published today ( Wednesday 06/03/2024 - 10:36 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® )

Also on site :

• WhiteFiber Announces Closing of $230.0 Million Convertible Senior Notes Offering and Zero-Strike Call Option Transaction
• Trump Says He Will Raise Tariffs on South Korea to 25%
• TikTok Data Center Outage Triggers Trust Crisis for New US Owners